07:00 , Oct 16, 2006 |  BC Week In Review  |  Clinical News

Saforis regulatory update

MOGN received an approvable letter from FDA for Saforis oral suspension to treat and prevent oral mucositis in which the agency asked for an additional Phase III trial. MOGN gained the oral formulation of glutamine...
07:00 , Oct 16, 2006 |  BioCentury  |  Finance

Ebb & Flow

Like many top tier biotechs, Genentech (DNA) does not provide any product-specific sales guidance, leaving Street forecasters to take their best guess at upcoming sales and earnings. While DNA may or may not care whether...
00:47 , Oct 13, 2006 |  BC Extra  |  Company News

FDA wants another Saforis trial

MGI Pharma (MOGN) said it received an approvable letter from FDA for Saforis oral suspension to treat and prevent oral mucositis in which the agency asked for an additional Phase III trial. MOGN said it...
01:18 , Jun 13, 2006 |  BC Extra  |  Company News

Saforis gets Priority Review

FDA accepted for filing and granted Priority Review to an NDA from MGI Pharma (MOGN) for Saforis oral suspension to treat and prevent oral mucositis in patients receiving mucotoxic cancer therapy. The PDUFA date is...
07:00 , Oct 18, 2004 |  BioCentury  |  Finance

EPS watch

EPS watch Company 3Q04 EPS est 3Q04 EPS actual Outcome Growth from 3Q03 10/15 cls Wk chg % chg Mcap chg 10/15 Mcap Abbott (ABT) $0.53 $0.53 Met 8% $41.36 $0.79...
07:00 , Oct 13, 2004 |  BC Extra  |  Financial News

MGI reports earnings

MOGN reported third quarter revenue of $55.5 million, up from $21.2 million in the same period in 2003. Sales of Aloxi palonosetron to prevent chemotherapy-induced nausea and vomiting were $47.6 million, up from $4.9 million...
07:00 , Sep 13, 2004 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Acambis (LSE:ACM; ACAM) CS First Boston Andrew Sinclair New Underperform Sinclair began coverage with a price of 291p. ACM closed Friday at 325p, unchanged on the...
07:00 , Sep 6, 2004 |  BioCentury  |  Finance

Ebb & Flow

After a busy summer, CoTherix last week got its IPO back on track. The deal was postponed in June, and in July, W. Scott Harkonen stepped down as CEO and a director. In its Thursday...
07:00 , Sep 6, 2004 |  BC Week In Review  |  Company News

Aesgen, MGI, Zycos deal

Aesgen shareholders are eligible for $58 million in regulatory and sales milestones, plus and a 5% royalty. MOGN plans to start a second Phase III trial of Saforis early next year. Also in early 2005,...
07:00 , Sep 6, 2004 |  BioCentury  |  Strategy

Asset accumulation

A few months ago, BioCentury spilled a lot of ink to deconstruct the NRDO model of no-research, development only companies being formed to scavenge for products or technologies that can be commercialized quickly and offer...